Literature DB >> 8950680

The phenotypic features of osteogenesis imperfecta resulting from a mutation of the carboxyl-terminal pro alpha 1 (I) propeptide that impairs the assembly of type I procollagen and formation of the extracellular matrix.

W G Cole1, C W Chow, J F Bateman, D O Sillence.   

Abstract

The features of a baby with lethal perinatal osteogenesis imperfecta (OI-II), resulting from the substitution of tryptophan 94 by cysteine in the carboxyl-terminal propeptide of pro alpha 1 (I) chains of type I procollagen, were studied. The limbs and torso were of normal length, shape, and proportion. Similarly, all bones were of relatively normal shape and the long bones showed normal metaphyseal modelling. These clinical and radiographic features were similar to those observed in another baby with OI-II resulting from a mutation of the carboxy-terminal propeptide of pro alpha 1 (I) chains but dissimilar from those reported in babies with OI-II resulting from helical mutations of type I collagen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8950680      PMCID: PMC1050794          DOI: 10.1136/jmg.33.11.965

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  10 in total

1.  The clinical features of osteogenesis imperfecta resulting from a non-functional carboxy terminal pro alpha 1(I) propeptide of type I procollagen and a severe deficiency of normal type I collagen in tissues.

Authors:  W G Cole; P E Campbell; J G Rogers; J F Bateman
Journal:  J Med Genet       Date:  1990-09       Impact factor: 6.318

2.  Mutations in the carboxyl-terminal propeptide of the pro alpha 1(I) chain of type I collagen result in defective chain association and produce lethal osteogenesis imperfecta.

Authors:  S D Chessler; G A Wallis; P H Byers
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

3.  A frameshift mutation results in a truncated nonfunctional carboxyl-terminal pro alpha 1(I) propeptide of type I collagen in osteogenesis imperfecta.

Authors:  J F Bateman; S R Lamande; H H Dahl; D Chan; T Mascara; W G Cole
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

Review 4.  Perinatal lethal osteogenesis imperfecta.

Authors:  W G Cole; R Dalgleish
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

5.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

6.  Frameshift mutation near the 3' end of the COL1A1 gene of type I collagen predicts an elongated Pro alpha 1(I) chain and results in osteogenesis imperfecta type I.

Authors:  M C Willing; D H Cohn; P H Byers
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

7.  Osteogenesis imperfecta: cloning of a pro-alpha 2(I) collagen gene with a frameshift mutation.

Authors:  T Pihlajaniemi; L A Dickson; F M Pope; V R Korhonen; A Nicholls; D J Prockop; J C Myers
Journal:  J Biol Chem       Date:  1984-11-10       Impact factor: 5.157

8.  BiP binds type I procollagen pro alpha chains with mutations in the carboxyl-terminal propeptide synthesized by cells from patients with osteogenesis imperfecta.

Authors:  S D Chessler; P H Byers
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

9.  Endoplasmic reticulum-mediated quality control of type I collagen production by cells from osteogenesis imperfecta patients with mutations in the pro alpha 1 (I) chain carboxyl-terminal propeptide which impair subunit assembly.

Authors:  S R Lamandé; S D Chessler; S B Golub; P H Byers; D Chan; W G Cole; D O Sillence; J F Bateman
Journal:  J Biol Chem       Date:  1995-04-14       Impact factor: 5.157

10.  The clinical features of homozygous alpha 2(I) collagen deficient osteogenesis imperfecta.

Authors:  A C Nicholls; G Osse; H G Schloon; H G Lenard; S Deak; J C Myers; D J Prockop; W R Weigel; P Fryer; F M Pope
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.